Drugs / MYL-1701P
MYL-1701P
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04674800 | Nov 2020 → Apr 2022 | diabetic macular edema | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 3 | NCT03610646 | Aug 2018 → Nov 2020 | diabetic macular edema | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MYL-1701P | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04674800 ↗ |
| Known as | aflibercept | “BACKGROUND: Phase-III INSIGHT study subgroup analyses observed best corrected visual acuity (BCVA) and central subfield thickness (CST) outcomes at Week 8/52 in diabetic...” PMID 42104207 ↗ May 20261“AIM: To evaluate the safety, efficacy and immunogenicity of biosimilar aflibercept (MYL-1701P) in participants with diabetic macular oedema who completed the 52-week global...” PMID 42373197 ↗ Jun 2026 |
| Known as | Yesafili | “BACKGROUND: Phase-III INSIGHT study subgroup analyses observed best corrected visual acuity (BCVA) and central subfield thickness (CST) outcomes at Week 8/52 in diabetic...” PMID 42104207 ↗ May 2026 |
| Modality | Protein / enzyme biologic | “AIM: To evaluate the safety, efficacy and immunogenicity of biosimilar aflibercept (MYL-1701P) in participants with diabetic macular oedema” PMID 42373197 ↗ Jun 2026 |
| Route | Intravitreal | “Subjects will receive intravitreal injections of MYL-1701P throughout the 52-week treatment period” NCT03610646 ↗ |